Protection of Chickens with Maternal Immunity Against Avian Influenza Virus (AIV) by Vaccination with a Novel Recombinant Newcastle Disease Virus Vector.
Age Factors
Animals
Chickens
Hemagglutinin Glycoproteins, Influenza Virus
/ immunology
Immunity, Maternally-Acquired
/ immunology
Influenza A Virus, H5N1 Subtype
/ immunology
Influenza in Birds
/ immunology
Newcastle Disease
/ immunology
Newcastle disease virus
/ immunology
Poultry Diseases
/ immunology
Vaccination
/ veterinary
Vaccines, Synthetic
/ administration & dosage
Viral Vaccines
/ administration & dosage
DIVA
H5N1
Newcastle disease
avian influenza
maternal immunity
vector vaccine
Journal
Avian diseases
ISSN: 1938-4351
Titre abrégé: Avian Dis
Pays: United States
ID NLM: 0370617
Informations de publication
Date de publication:
01 12 2020
01 12 2020
Historique:
received:
06
02
2020
accepted:
18
05
2020
entrez:
21
12
2020
pubmed:
22
12
2020
medline:
27
8
2021
Statut:
ppublish
Résumé
Newcastle disease virus (NDV) vectors expressing avian influenza virus (AIV) hemagglutinin of subtype H5 protect specific pathogen-free chickens from Newcastle disease and avian influenza. However, maternal AIV antibodies (AIV-MDA+) are known to interfere with active immunization by influencing vaccine virus replication and gene expression, resulting in inefficient protection. To overcome this disadvantage, we inserted a transgene encoding a truncated soluble hemagglutinin (HA) in addition to the gene encoding membrane-bound HA from highly pathogenic avian influenza virus (HPAIV) H5N1 into lentogenic NDV Clone 30 genome (rNDVsolH5_H5) to overexpress H5 antigen. Vaccination of 3-wk-old AIV-MDA+ chickens with rNDVsolH5_H5 and subsequent challenge infection with HPAIV H5N1 3 wk later resulted in 100% protection. Vaccination of younger chickens with higher AIV-MDA levels 1 and 2 wk after hatch resulted in protection rates of 40% and 85%, respectively. However, all vaccinated chickens showed strongly reduced shedding of challenge virus compared with age-matched, nonvaccinated control chickens. All control chickens succumbed to the HPAIV infection with a grading in disease progression between the three groups, indicating the influence of AIV-MDAs even at a low level. Furthermore, the shedding and serologic data gathered after immunization indicate sufficient replication of the vaccine virus, which leads to the assumption that lower protection rates in younger AIV-MDA+ chickens are caused by an H5 antigen-specific block and not by the interference of the AIV-MDA and the vaccine virus itself. In summary, solid protective efficacy and reduced virus transmission were achieved in 3-wk-old AIV-MDA+ chickens, which is relevant especially in regions endemically infected with HPAIV H5N1.
Identifiants
pubmed: 33347549
pii: 445087
doi: 10.1637/aviandiseases-D-20-00014
doi:
Substances chimiques
Hemagglutinin Glycoproteins, Influenza Virus
0
Vaccines, Synthetic
0
Viral Vaccines
0
Types de publication
Journal Article
Randomized Controlled Trial, Veterinary
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM